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background:  Different strategies have been evaluated for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). We 
sought to evaluate the efficacy and safety of different approaches compared to standard therapy with warfarin.
Methods:  We conducted electronic database searches of phase III randomized controlled trials (RCT). Efficacy outcomes were stroke 
or systemic embolism (SSE) and all-cause mortality. Safety outcome was major bleeding or procedure related complications. A random-
effect model was used to obtain a summary effect. Odds ratios (OR) and 95% confidence intervals (CI) were computed using the Mantel-
Haenszel method.
results:  Eight RCTs were included (n=80,684 patients). The comparison groups were novel oral anticoagulants (NOAC), and Watchman 
left atrial appendage occlusion device (Device) against warfarin. There was a significant difference favoring NOAC for SSE (OR 0.83, 
95% CI 0.72-0.97; p=0.01), all-cause mortality (OR 0.88, 95% CI 0.83-0.93; p<0.001) and safety outcomes (OR 0.79, 95% CI 0.64-0.97; 
p=0.026) compared to Device. No evidence of significant publication bias was found.
Conclusion:  NOAC is superior to warfarin and Device when compared to warfarin as standard therapy for stroke prevention in NVAF. 
Device is a reasonable non-inferior alternative to warfarin for stroke prevention when anticoagulation is contraindicated.
 
